Is compounded tirzepatide safe?

The same answer as its cousin, with different dates. Nobody has run the study that would tell you, the FDA does not review compounded products before they are sold, and the agency has documented specific problems. What is different about tirzepatide is the timeline and the fact that it is a newer molecule with less accumulated real world data of any kind.

Tirzepatide's clock ran ahead

Tirzepatide is the molecule in Mounjaro and Zepbound. Large scale compounding of it was allowed because the approved product was in shortage.

The FDA determined that shortage was resolved on 19 December 2024. Enforcement discretion then ended on 18 February 2025 for state licensed pharmacies compounding under section 503A, and 19 March 2025 for registered outsourcing facilities under section 503B.

That was roughly two months ahead of the semaglutide timeline. If you started on compounded tirzepatide during 2025, the legal ground under it changed earlier than most people realised.

On 1 May 2026 the FDA went further and proposed removing tirzepatide, along with semaglutide and liraglutide, from the list of bulk substances outsourcing facilities may compound from, on the basis that there is no clinical need for it. The comment period closed on 29 June 2026.

What the FDA has documented

The agency's concerns are largely the same across both molecules, because they are concerns about compounding at scale rather than about the drug itself.

Dosing errors, including patients self administering the wrong amount and patients being prescribed beyond the approved label through larger doses, more frequent dosing, or faster titration.

Ingredient quality, addressed with an import alert on GLP-1 raw ingredients with potential quality problems.

Cold chain failures, with product arriving warm or inadequately iced.

Counterfeit and falsely labelled product.

Reported adverse events. More than 730 relating to compounded tirzepatide as of 31 May 2026.

The comparison that does not exist

There is a real world comparison of compounded and approved semaglutide, covered on our page about whether it works. There is no equivalent for tirzepatide. Nobody has compared compounded tirzepatide to Zepbound or Mounjaro in a study worth citing.

That is not a small gap. Tirzepatide works on two receptor pathways rather than one, and in the approved product's trials it produced larger average weight loss than semaglutide did in its own. If you are choosing compounded tirzepatide partly on the strength of those trial results, it is worth being clear that those results belong to the approved product, not to a compounded copy of it.

Two molecules that cannot be compounded at all

While we are on this: retatrutide and cagrilintide have never been FDA approved for anything. Because there is no approved product, there is no lawful route to compound them. If a provider offers you either one, that is not a grey area.

The approved product got much cheaper

Cost is usually the reason people choose compounded. That calculation changed in 2026. Zepbound is one of the products available through the Medicare GLP-1 Bridge at fifty dollars a month for eligible beneficiaries, and the approved products became available at substantially reduced cash prices through a federal purchasing channel. Whether either route fits you depends on your coverage, but it is worth checking before you decide on price alone.

What to ask

• Is this FDA approved tirzepatide, or compounded?
• Which facility compounds it, and are they registered with the FDA?
• Does my dose and titration schedule match the approved label, and if not, why?
• Am I drawing my own dose from a vial?
• What is the total monthly cost, and have I checked what the approved product would cost me now?

Sources

• FDA, "FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize"
• FDA, "FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss"
• FDA, "FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List"; Federal Register document 2026-08552
• Centers for Medicare and Medicaid Services, Medicare GLP-1 Bridge
• Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 2022. doi:10.1056/nejmoa2206038

How we verify: see /how-we-verify.

Keep reading

How compounded tirzepatide compares to Zepbound, at /guides/compounded-tirzepatide-vs-zepbound.

What compounded GLP-1s cost and why they are cheaper, at /guides/compounded-glp1-cost.